Bortezomib before and after high‐dose therapy in transplant‐eligible patients with newly diagnosed multiple myeloma: Long‐term overall survival after more than 10 years of follow‐up from the phase III HOVON‐65/GMMG‐HD4 trial

Documenti analoghi

• Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG ‐ MM5 Trial
  di: Tim Richardson, et al.
  Pubblicazione: (2025)
• Time‐restricted versus standard‐duration immunosuppression after allogeneic hematopoietic stem cell transplantation: Results of the prospective randomized HOVON‐96 trial
  di: Annoek E. C. Broers, et al.
  Pubblicazione: (2024)
• Prognostic value of measurable residual disease in high‐risk MDS after intensive chemotherapy in HOVON‐SAKK studies
  di: Coen R. Veenstra, et al.
  Pubblicazione: (2026)
• Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial
  di: Paul Richardson, et al.
  Pubblicazione: (2025)
• The application in Germany of the Washington Convention concerning the employment of women before and after childbirth
  di: Hans Goldschmidt
  Pubblicazione: (1927)